{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:47:06Z","timestamp":1785934026397,"version":"3.56.0"},"publisher-location":"Berlin, Heidelberg","reference-count":65,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/164_2026_833","type":"book-chapter","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:53:27Z","timestamp":1785930807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Boron-Containing Drug Candidates in Clinical Trials"],"prefix":"10.1007","author":[{"given":"Billy","family":"Vuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Sanghai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shaharyar Khan","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey K.","family":"Tranmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"1","key":"833_CR1","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01445-25","volume":"70","author":"AS Abdelsattar","year":"2026","unstructured":"Abdelsattar AS, Kikiowo B, Abutaleb NS, Dove AS, Seleem MN (2026) Chlamydia trachomatis infections. Antimicrob Agents Chemother 70(1):e0144525","journal-title":"Antimicrob Agents Chemother"},{"key":"833_CR2","unstructured":"ACOZI-KIDS [Internet]. [cited 2026 Feb 3]. Available from: https:\/\/dndi.org\/global-networks\/acozi-kids\/"},{"key":"833_CR3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.2023.41.6_suppl.176","volume":"41","author":"RR Aggarwal","year":"2023","unstructured":"Aggarwal RR, Zhang J, Zhu X, Monk P, Jones RJ, Linch MD et al (2023) First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: phase 2a final results. J Clin Oncol 41:176","journal-title":"J Clin Oncol"},{"issue":"3","key":"833_CR4","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35728","volume":"131","author":"J Ahmed","year":"2025","unstructured":"Ahmed J, Janku F, Karp DD, Piha-Paul SA, Tsimberidou AM, Yap TA et al (2025) A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers. Cancer 131(3):e35728","journal-title":"Cancer"},{"key":"833_CR5","unstructured":"Anacor Pharmaceuticals, Inc (2007) Prospectus Registration Statement SEC Form S-1 [Internet]. United States Securities and Exchange Commission [cited 2026 Jul 2]. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1411158\/000104746907006803\/a2179512zs-1.htm"},{"key":"833_CR6","unstructured":"Annual report which provides a comprehensive overview of the company for the past year [Internet]. 2025 [cited 2026 Jul 1]. Available from: https:\/\/investor.an2therapeutics.com\/static-files\/1ab5d823-647b-49a3-a3e6-2375816204f3"},{"key":"833_CR7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-3-031-82591-0_18","volume-title":"Neutron capture therapy: principles and applications","author":"T Asano","year":"2025","unstructured":"Asano T, Kirihata M (2025) A commercially available BNCT drug: Steboronine from Stella pharma. In: Sauerwein WAG, Wittig A, Moss RL, Nakagawa Y, Ono K (eds) Neutron capture therapy: principles and applications, 2nd edn. Springer, pp 251\u2013258","edition":"2"},{"key":"833_CR8","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1016\/j.bmcl.2006.08.130","volume":"16","author":"SJ Baker","year":"2006","unstructured":"Baker SJ, Akama T, Zhang Y, Sauro V, Pandit C, Singh R et al (2006) Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases. Bioorg Med Chem Lett 16:5963\u20135967","journal-title":"Bioorg Med Chem Lett"},{"key":"833_CR9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/cac2.12582","volume":"44","author":"RF Barth","year":"2024","unstructured":"Barth RF, Gupta N, Kawabata S (2024) Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer Commun 44:893\u2013909","journal-title":"Cancer Commun"},{"key":"833_CR10","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1021\/jm050676a","volume":"48","author":"SJ Benkovic","year":"2005","unstructured":"Benkovic SJ, Baker SJ, Alley MRK, Woo Y, Zhang Y, Akama T et al (2005) Identification of Borinic esters as inhibitors of bacterial cell growth and bacterial Methyltransferases, CcrM and MenH. J Med Chem 48:7468\u20137476","journal-title":"J Med Chem"},{"key":"833_CR11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ph17030351","volume":"17","author":"A Bernal","year":"2024","unstructured":"Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G (2024) The current therapeutic landscape for metastatic prostate cancer. Pharmaceuticals. 17:351","journal-title":"Pharmaceuticals."},{"issue":"7","key":"833_CR12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1535-7163.MCT-22-0721","volume":"22","author":"B Borek","year":"2023","unstructured":"Borek B, Nowicka J, Gzik A, Dziegielewski M, Jedrzejczak K, Brzezinska J et al (2023) Arginase 1\/2 inhibitor OATD-02: from discovery to first-in-man setup in cancer immunotherapy. Mol Cancer Ther 22(7):807\u2013817","journal-title":"Mol Cancer Ther"},{"key":"833_CR13","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","volume":"10","author":"PF Bross","year":"2004","unstructured":"Bross PF, Kane R, Farrell AT, Abraham S, Benson K, Brower ME et al (2004) Approval summary for Bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 10:3954\u20133964","journal-title":"Clin Cancer Res"},{"key":"833_CR14","unstructured":"Caroll J (2010) Xconomy: phenomix forced to close shop after partner dumps pact [Internet]. [cited 2026 Feb 20]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/xconomy-phenomix-forced-to-close-shop-after-partner-dumps-pact"},{"key":"833_CR15","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1021\/jm800390n","volume":"51","author":"BA Connolly","year":"2008","unstructured":"Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT et al (2008) Dipeptide Boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem 51:6005\u20136013","journal-title":"J Med Chem"},{"issue":"9","key":"833_CR16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/13543784.16.9.1459","volume":"16","author":"CC Cunningham","year":"2007","unstructured":"Cunningham CC (2007) Talabostat. Expert Opin Investig Drugs 16(9):1459\u20131465","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"833_CR17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41591-024-02829-7","volume":"30","author":"AH Diacon 3rd","year":"2024","unstructured":"Diacon AH 3rd, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V et al (2024) A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nat Med 30(3):896\u2013904","journal-title":"Nat Med"},{"key":"833_CR18","unstructured":"DRC approves the use of acoziborole, a breakthrough one-day oral treatment against sleeping sickness. [Internet]. 2026 [cited 2026 Jun 12]. Available from: https:\/\/dndi.org\/press-releases\/2026\/drc-approves-use-acoziborole-breakthrough-one-day-oral-treatment-against-sleeping-sickness\/"},{"key":"833_CR19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-9-263","volume":"9","author":"RM Eager","year":"2009","unstructured":"Eager RM, Cunningham CC, Senzer NN, Stephenson J Jr, Anthony SP, O\u2019Day SJ et al (2009) Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma. BMC Cancer 9:263","journal-title":"BMC Cancer"},{"issue":"Suppl 2","key":"833_CR20","doi-asserted-by":"crossref","first-page":"ofac492.1357","DOI":"10.1093\/ofid\/ofac492.1357","volume":"9","author":"PB Eckburg","year":"2022","unstructured":"Eckburg PB, Clarke D, Long J, Chanda S, Krause KM, Easom E et al (2022) 1727. Phase 1b dose-ranging study demonstrates tolerability and pharmacokinetics (PK) of Oral Epetraborole at the predicted therapeutic dosage for Mycobacterium avium Complex (MAC) lung disease. Open Forum Infect Dis 9(Suppl 2):ofac492.1357","journal-title":"Open Forum Infect Dis"},{"issue":"22","key":"833_CR21","doi-asserted-by":"crossref","first-page":"19988","DOI":"10.1021\/acs.jmedchem.4c01429","volume":"67","author":"M Failla","year":"2024","unstructured":"Failla M, Molaro MC, Schiano ME, Serafini M, Tiburtini GA, Gianquinto E et al (2024) Opportunities and challenges of arginase inhibitors in cancer: a medicinal chemistry perspective. J Med Chem 67(22):19988\u201320021","journal-title":"J Med Chem"},{"issue":"12","key":"833_CR22","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/ph18121798","volume":"18","author":"MB Frooman","year":"2025","unstructured":"Frooman MB, Deb MK, Peters J, Leggett S, Sanghai N, Rizvi NZ et al (2025) Recent advancements in the diversification and applications of boron-containing compounds in medicinal chemistry\u2020. Pharmaceuticals 18(12):1798","journal-title":"Pharmaceuticals"},{"issue":"10","key":"833_CR23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01156-21","volume":"65","author":"US Ganapathy","year":"2021","unstructured":"Ganapathy US, Gengenbacher M, Dick T (2021) Epetraborole is active against mycobacterium abscessus. Antimicrob Agents Chemother 65(10):e0115621","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"833_CR24","doi-asserted-by":"crossref","first-page":"S431","DOI":"10.1093\/ofid\/ofy210.1232","volume":"5","author":"B Geibel","year":"2018","unstructured":"Geibel B, Dowell J, Dickerson D, Henkel T (2018) 1401. A randomized, double-blind, placebo-controlled study of the safety and pharmacokinetics of single and repeat doses of VNRX-5133 in healthy subjects. Open Forum Infect Dis 5(Suppl 1):S431","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"833_CR25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1753944710387808","volume":"5","author":"A G\u00f3mez-Outes","year":"2011","unstructured":"G\u00f3mez-Outes A, Su\u00e1rez-Gea ML, Lecumberri R, Rocha E, Pozo-Hern\u00e1ndez C, Vargas-Castrill\u00f3n E (2011) New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 5(1):33\u201359","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"16","key":"833_CR26","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.3390\/cancers14163967","volume":"14","author":"MM Grzybowski","year":"2022","unstructured":"Grzybowski MM, Sta\u0144czak PS, Pomper P, B\u0142aszczyk R, Borek B, Gzik A et al (2022) OATD-02 validates the benefits of pharmacological inhibition of arginase 1 and 2 in cancer. Cancers (Basel) 14(16):3967","journal-title":"Cancers (Basel)"},{"key":"833_CR27","first-page":"1","volume":"2","author":"MM Grzybowski","year":"2025","unstructured":"Grzybowski MM, U\u00e7al Y, Muchowicz A, Rejczak T, Kikulska A, G\u0142uchowska KM et al (2025) Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity. Sci Rep 2:1\u201316","journal-title":"Sci Rep"},{"issue":"5","key":"833_CR28","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1128\/AAC.02940-15","volume":"60","author":"A Gupta","year":"2016","unstructured":"Gupta A, Monteferrante C, Rasina D, Leitis G, Randall CP, Tomlinson JH et al (2016) A polymorphism in leuS confers reduced susceptibility to GSK2251052 in a clinical isolate of Staphylococcus aureus. Antimicrob Agents Chemother 60(5):3219\u20133221","journal-title":"Antimicrob Agents Chemother"},{"key":"833_CR29","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1021\/acs.jmedchem.9b01976","volume":"63","author":"SJ Hecker","year":"2020","unstructured":"Hecker SJ, Reddy KR, Lomovskaya O, Griffith DC, Rubio-Aparicio D, Nelson K et al (2020) Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum inhibitor of serine and Metallo-\u03b2-lactamases. J Med Chem 63:7491\u20137507","journal-title":"J Med Chem"},{"issue":"10","key":"833_CR30","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00784-25","volume":"69","author":"MP Hern\u00e1ndez-mitre","year":"2025","unstructured":"Hern\u00e1ndez-mitre MP, Wallis SC, Loutit JS, Griffith DC, Roberts JA (2025) Phase 1, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the safety, tolerability, and pharmacokinetics of intravenous xeruborbactam (QPX7728) in healthy adult subjects. Antimicrob Agents Chemother 69(10):e0078425","journal-title":"Antimicrob Agents Chemother"},{"key":"833_CR31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.radonc.2020.11.001","volume":"155","author":"K Hirose","year":"2021","unstructured":"Hirose K, Konno A, Hiratsuka J, Yoshimoto S, Kato T, Suzuki M et al (2021) Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial. Radiother Oncol 155:182\u2013187","journal-title":"Radiother Oncol"},{"issue":"3","key":"833_CR32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0360-3016(98)00069-8","volume":"41","author":"V Horn","year":"1998","unstructured":"Horn V, Sl\u00e1nsk\u00fd J, Janku I, \u0160trouf O, \u0160ourek K, Tovary\u0161 F (1998) Disposition and tissue distribution of boron after infusion of borocaptate sodium in patients with malignant brain tumors. Int J Radiat Oncol Biol Phys 41(3):631\u2013638","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"833_CR33","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","volume":"62","author":"A Krajnc","year":"2019","unstructured":"Krajnc A, Brem J, Hinchliffe P, Calvopi\u00f1a K, Panduwawala TD, Lang PA et al (2019) Bicyclic Boronate VNRX-5133 inhibits Metallo- and serine-\u03b2-lactamases. J Med Chem 62(18):8544\u20138556","journal-title":"J Med Chem"},{"issue":"4","key":"833_CR34","doi-asserted-by":"crossref","first-page":"p463","DOI":"10.1016\/S1473-3099(22)00660-0","volume":"23","author":"VKB Kumeso","year":"2023","unstructured":"Kumeso VKB, Kalonji WM, Rembry S, Mordt OV, Tete DN, Pr\u00eatre A et al (2023) Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei: a multicentre, open-label, single-arm, phase 2\/3 trial. Lancet Infect Dis 23(4):p463\u2013p470","journal-title":"Lancet Infect Dis"},{"issue":"19","key":"833_CR35","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","volume":"60","author":"X Li","year":"2017","unstructured":"Li X, Hernandez V, Rock FL, Choi W, Mak YSL, Mohan M et al (2017) Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem 60(19):8011\u20138026","journal-title":"J Med Chem"},{"issue":"6","key":"833_CR36","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu B, Trout REL, Chu G-H, McGarry D, Jackson RW, Hamrick JC et al (2020) Discovery of Taniborbactam (VNRX-5133): a broad-Spectrum serine- and Metallo-\u03b2-lactamase inhibitor for Carbapenem-resistant bacterial infections. J Med Chem 63(6):2789\u20132801","journal-title":"J Med Chem"},{"issue":"2","key":"833_CR37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/154405910808700208","volume":"87","author":"Q Luan","year":"2008","unstructured":"Luan Q, Desta T, Chehab L, Sanders VJ, Plattner J, Graves DT (2008) Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res 87(2):148\u2013152","journal-title":"J Dent Res"},{"issue":"3","key":"833_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph15030264","volume":"15","author":"K Messner","year":"2022","unstructured":"Messner K, Vuong B, Tranmer GK (2022) The boron advantage: the evolution and diversification of Boron\u2019s applications in medicinal chemistry. Pharmaceuticals 15(3):1\u201333","journal-title":"Pharmaceuticals"},{"issue":"1","key":"833_CR39","volume":"3","author":"A Naing","year":"2024","unstructured":"Naing A, Papadopoulos KP, Pishvaian MJ, Rahma O, Hanna GJ, Garralda E et al (2024) First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours. BMJ Oncol 3(1):e000249","journal-title":"BMJ Oncol"},{"key":"833_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-4615-1285-1_16","volume-title":"Frontiers in neutron capture therapy","author":"Y Nakagawa","year":"2001","unstructured":"Nakagawa Y, Kyonghon P, Kitamura K, Kageji T, Minobe T (2001) Long term follow up in patients who underwent boron neutron capture therapy. In: Hawthorne MF, Shelly K, Wiersema RJ (eds) Frontiers in neutron capture therapy, 1st edn. Springer, Boston, pp 141\u2013144","edition":"1"},{"key":"833_CR41","unstructured":"New single-dose oral treatment approved to fight sleeping sickness [Internet]. 2026 [cited 2026 Jun 12]. Available from: https:\/\/www.global-health-edctp3.europa.eu\/news-and-events\/news\/new-single-dose-oral-treatment-approved-fight-sleeping-sickness-2026-03-18_en"},{"key":"833_CR42","unstructured":"PAION AG Regulatory Release Archives (2008) Public offer and admission to trading of up to 7,850,000 ordinary no-par value bearer shares (St\u00fcckaktien) [Internet]. PAION AG Regulatory Release Archives [cited 2026 Jun 17]. pp 39\u201340. Available from: https:\/\/www.paion.com\/uploads\/media\/frankfurt-35606-v1-billigungsfassung-16-05-2008_02.pdf"},{"issue":"4","key":"833_CR43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1463-1326.2010.01195.x","volume":"12","author":"HMR Pattzi","year":"2010","unstructured":"Pattzi HMR, Pitale S, Alpizar M, Bennett C, O\u2019Farrell AM, Li J et al (2010) Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab 12(4):348\u2013355","journal-title":"Diabetes Obes Metab"},{"key":"833_CR44","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/gt.2012.32","volume":"19","author":"MS Penn","year":"2012","unstructured":"Penn MS, Pastore J, Miller T, Aras R (2012) SDF-1 in myocardial repair. Gene Ther 19:583\u2013587","journal-title":"Gene Ther"},{"issue":"5","key":"833_CR45","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2007-07-100651","volume":"111","author":"R Piva","year":"2008","unstructured":"Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D et al (2008) CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5):2765\u20132775","journal-title":"Blood"},{"key":"833_CR46","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pur\u00e9","year":"2018","unstructured":"Pur\u00e9 E, Blomberg R (2018) Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene 37:4343\u20134357","journal-title":"Oncogene"},{"issue":"4","key":"833_CR47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.08008.x","volume":"148","author":"E Sanchez","year":"2010","unstructured":"Sanchez E, Li M, Steinberg JA, Wang C, Shen J, Bonavida B et al (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and and melphalan. Br J Haematol 148(4):569\u2013581","journal-title":"Br J Haematol"},{"key":"833_CR48","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3390\/cancers16050869","volume":"16","author":"M Sato","year":"2024","unstructured":"Sato M, Hirose K, Takeno S, Aihara T, Nihei K, Takai Y et al (2024) Safety of boron neutron capture therapy with borofalan (10 B) and its efficacy on recurrent head and neck cancer: real-world outcomes from nationwide post-marketing surveillance. Cancers (Basel) 16:869","journal-title":"Cancers (Basel)"},{"key":"833_CR49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","volume":"128","author":"NK Smith","year":"2019","unstructured":"Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94\u2013105","journal-title":"Neurochem Int"},{"key":"833_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda SM, Bennett MK, Chen J, Emberley E, Huang T, Janes JR et al (2017) Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J Immunother Cancer 5:101","journal-title":"J Immunother Cancer"},{"key":"833_CR51","unstructured":"Talabostat trials put on hold on discouraging data [Internet] (2007) [cited 2026 Mar 28]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/talabostat-trials-put-on-hold-on-discouraging-data"},{"issue":"8","key":"833_CR52","doi-asserted-by":"crossref","first-page":"e00240","DOI":"10.1128\/AAC.00240-19","volume":"63","author":"D Tenero","year":"2019","unstructured":"Tenero D, Derimanov G, Carlton A, Tonkyn J, Davies M, Cozens S et al (2019) First-time-in-human study and prediction of early bactericidal activity for GSK3036656, a potent Leucyl-tRNA Synthetase inhibitor for tuberculosis treatment. Antimicrob Agents Chemother 63(8):e00240\u2013e00219","journal-title":"Antimicrob Agents Chemother"},{"key":"833_CR53","unstructured":"Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam [Internet]. 2024 [cited 2026 Jun 22]. Available from: https:\/\/www.businesswire.com\/news\/home\/20240223169844\/en\/Venatorx-and-Melinta-Provide-Update-on-Status-of-U.S.-New-Drug-Application-for-Cefepime-Taniborbactam"},{"key":"833_CR54","unstructured":"Venatorx Everest Medicines Accept New Drug Application for Cefepime Taniborbactam [Internet]. 2026 [cited 2026 Jun 22]. Available from: https:\/\/clival.com\/news\/venatorx-everest-medicines-accept-new-drug-application-for-cefepime-taniborbactam"},{"issue":"8","key":"833_CR55","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1080\/10428194.2016.1263842","volume":"58","author":"DT Vogl","year":"2017","unstructured":"Vogl DT, Martin TG, Vij R, Hari P, Joseph R, Siegel D et al (2017) Phase I\/II study of the novel proteasome inhibitor delanzomib ( CEP-18770 ) for relapsed and refractory multiple myeloma. Leuk Lymphoma 58(8):1872\u20131879","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"833_CR56","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.3390\/jcm11195728","volume":"11","author":"D Von Lewinski","year":"2022","unstructured":"Von Lewinski D, Benedikt M, Alber H, Debrauwere J, Smits PC, \u00c9des I et al (2022) Dutogliptin in combination with Filgrastim in early recovery post-myocardial infarction \u2013 the REC-DUT-002 trial. J Clin Med 11(19):5728","journal-title":"J Clin Med"},{"key":"833_CR57","doi-asserted-by":"crossref","unstructured":"Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. Cefepime\u2013Taniborbactam in Complicated Urinary Tract Infection. N Engl J Med 2024;390(7):611\u2013622","DOI":"10.1056\/NEJMoa2304748"},{"issue":"4","key":"833_CR58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1358\/dof.2007.032.04.1091152","volume":"32","author":"Y Wang","year":"2007","unstructured":"Wang Y, Mealy N, Serradell N, Bolos J, Rosa E (2007) Flovagatran Sodium. Drugs Future 32(4):310\u2013314","journal-title":"Drugs Future"},{"issue":"12","key":"833_CR59","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1021\/acschembio.5c00705","volume":"20","author":"M Wang","year":"2025","unstructured":"Wang M, He Y, Cohen SA, Strohm AR, Shetye G, Franzblau SG et al (2025) Selectivity of the time-dependent M. Tuberculosis LeuRS inhibitor Ganfeborole is driven by target vulnerability. ACS Chem Biol 20(12):2955\u20132965","journal-title":"ACS Chem Biol"},{"key":"833_CR60","unstructured":"Weintraub A (2021) Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer [Internet]. [cited 2026 Mar 28]. Available from: https:\/\/www.fiercebiotech.com\/research\/once-failed-cancer-drug-from-bioxcel-ramps-up-immunotherapy-mouse-models-pancreatic-cancer"},{"issue":"3","key":"833_CR61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/cas.12602","volume":"106","author":"P Wongthai","year":"2015","unstructured":"Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R et al (2015) Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci 106(3):279\u2013286","journal-title":"Cancer Sci"},{"issue":"9","key":"833_CR62","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1016\/j.apsb.2025.07.009","volume":"15","author":"Y Wu","year":"2025","unstructured":"Wu Y, Wang X, Sun X, Gao X, Zhang S, Shen J et al (2025) Fibroblast activation protein targeting radiopharmaceuticals: from drug design to clinical translation. Acta Pharm Sin B 15(9):4511\u20134542","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"833_CR63","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1517\/13543784.2012.710198","volume":"21","author":"H Zhao","year":"2012","unstructured":"Zhao H, Jiang H, Xiang B (2012) Discontinued drugs in 2011: cardiovascular drugs. Expert Opin Investig Drugs 21(10):1449\u20131462","journal-title":"Expert Opin Investig Drugs"},{"key":"833_CR64","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/cancers18030498","volume":"18","author":"D Zheng","year":"2026","unstructured":"Zheng D, Han G, Lemus ODM, Podgorsak A, Webster M, Li F et al (2026) Boron neutron capture therapy: a technology-driven renaissance. Cancers (Basel) 18:498","journal-title":"Cancers (Basel)"},{"issue":"2","key":"833_CR65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.62347\/HBBE6868","volume":"14","author":"T Zhou","year":"2024","unstructured":"Zhou T, Igawa K, Kasai T, Sadahira T, Wang W, Watanabe T (2024) The current status and novel advances of boron neutron capture therapy clinical trials. Am J Cancer Res 14(2):429\u2013447","journal-title":"Am J Cancer Res"}],"container-title":["Handbook of Experimental Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2026_833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:53:35Z","timestamp":1785930815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2026_833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":65,"URL":"https:\/\/doi.org\/10.1007\/164_2026_833","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"6 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}